Ribavirin and abacavir drug interaction in HIV–HCV coinfected patients: fact or fiction?

Objective(s):To examine the impact of ribavirin and abacavir coadministration on hepatitis C virus (HCV) virological response and trough ribavirin plasma concentration (Cmin) in HIV–HCV coinfected patients. Design:Pharmacokinetic substudy on patients from the ANRS CO-13 HEPAVIH cohort. Methods:Patients receiving ribavirin–pegylated interferon for whom a ribavirin steady state Cmin was prospectively determined were included. Rapid virological response (RVR), early virological response (EVR) and sustained virological response (SVR) as well as HCV-RNA decline were evaluated. Results:Overall, 124 HIV–HCV coinfected patients (95% on antiretroviral therapy) were enrolled. Of these patients, 22% received abacavir. The overall median (interquartile range) ribavirin Cmin was 1.6 mg/l (1.2–2.2) with no statistical difference between abacavir users and nonusers [1.5 mg/l (0.99–2.1) and 1.7 (1.2–2.3), P = 0.15]. RVR and EVR were 52 and 72%, respectively. There was no difference observed in the proportion of abacavir users vs. nonusers achieving RVR (respectively 59 vs. 50%, P = 0.40) or EVR (72 vs. 73%, P = 0.94), or in the HCV-RNA decline at week 4 [−2.24 log10 IU/ml, (−3.58; −0.81) and −1.27 (−2.8; −0.47) P = 0.28] or at week 12 [−1.76 log10 IU/ml (−3.67; −0.35) and −1.85 (−3.13; −1.13) (P = 0.58)]. The SVR rate was 45% for abacavir users and 24% for abacavir nonusers, but the difference was not statistically significant (P = 0.059). Conclusion:In our study, there was no evidence that abacavir affected HCV treatment outcomes and the ribavirin Cmin was similar in abacavir users and nonusers, confirming the absence of pharmacokinetic interaction between abacavir and ribavirin. An abacavir-containing regimen is, therefore, a well tolerated treatment alternative for coinfected patients starting HCV treatment.

[1]  J. Benito,et al.  Prediction of response to pegylated interferon plus ribavirin in HIV/hepatitis C virus (HCV)-coinfected patients using HCV genotype, IL28B variations, and HCV-RNA load. , 2012, Journal of hepatology.

[2]  A. Curran,et al.  Abacavir Coadministration Does Not Interfere with the Suppressive Activity of Ribavirin in An HCV Replicon System , 2011, Antiviral therapy.

[3]  F. Stanke-Labesque,et al.  [Evidence-based therapeutic drug monitoring for ribavirine]. , 2011, Therapie.

[4]  A. Neumann,et al.  Very early prediction of response to HCV treatment with PEG‐IFN‐alfa‐2a and ribavirin in HIV/HCV‐coinfected patients , 2011, Journal of viral hepatitis.

[5]  F. Stanke-Labesque,et al.  [Evidence-based therapeutic drug monitoring for ribavirine]. , 2011, Therapie.

[6]  D. Neau,et al.  The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): Early findings, 2006-2010 , 2010, BMC infectious diseases.

[7]  Ross J. Harris,et al.  Causes of death in HIV-1-infected patients treated with antiretroviral therapy, 1996-2006: collaborative analysis of 13 HIV cohort studies. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[8]  J. Kostman,et al.  The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients , 2010, Antiviral therapy.

[9]  P. Marquet,et al.  Ribavirin therapeutic drug monitoring: why, when and how? , 2009, Fundamental & clinical pharmacology.

[10]  M. Vogel,et al.  The treatment of chronic hepatitis C virus infection in HIV co-infection , 2009, European Journal of Medical Research.

[11]  V. Soriano,et al.  Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. , 2008, The Journal of antimicrobial chemotherapy.

[12]  C. Tural,et al.  Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. , 2008, The Journal of antimicrobial chemotherapy.

[13]  J. Gatell,et al.  Abacavir does not Influence the Rate of Virological Response in HIV–HCV-Coinfected Patients Treated with Pegylated Interferon and Weight-Adjusted Ribavirin , 2008, Antiviral therapy.

[14]  V. Soriano,et al.  Low Response to Pegylated Interferon plus Ribavirin in HIV-Infected Patients with Chronic Hepatitis C Treated with Abacavir , 2008, Antiviral therapy.

[15]  J. Pineda,et al.  Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. , 2007, The Journal of antimicrobial chemotherapy.

[16]  C. Tural,et al.  Baseline factors prognostic of sustained virological response in patients with HIV–hepatitis C virus co-infection , 2007, AIDS.

[17]  F. Carrat,et al.  Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? , 2007, Journal of acquired immune deficiency syndromes.

[18]  Giorgio Palù,et al.  Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV co-infected patients. , 2005, Journal of hepatology.

[19]  N. Margot,et al.  In Vitro Combination Studies of Tenofovir and Other Nucleoside Analogues with Ribavirin against HIV-1 , 2005, Antiviral therapy.

[20]  Henry J. Kaiser,et al.  Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Department of Health and Human Services and Henry J. Kaiser Family Foundation. , 1998, MMWR. Recommendations and reports : Morbidity and mortality weekly report. Recommendations and reports.